Xultophy (insulin degludec;liraglutide)
- Region
- 🇪🇺 EU
- Active substance
- insulin degludec;liraglutide
- Company
- Novo Nordisk A/S
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus, Type 2
- CHMP opinion
- Fri 25 Jul 2014
- EU approval
- Thu 18 Sep 2014
- Application
- EMEA/H/C/002647
- ATC
- A10AE56
- Official record
- www.ema.europa.eu
Indication
Xultophy is indicated for the treatment of adults with type-2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or basal insulin do not provide adequate glycaemic control.
Regulatory milestones
No milestones recorded in the last year.
Follow Xultophy
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.